Hypericum perforatum extracts in the treatment of mild to moderate depression - Clinical and pharmacological aspects;Hypericum-perforatum-extrakt bei der behandlung leichter bis mittelschwerer depressionen - Klinische und pharmakologische aspekte

Nervenarzt

Volumn 73, Issue 7, 2002, Pages 600-612

  Laakmann, G ^a   Jahn, G ^a   Schule C ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Depression; Hyperforin; Hypericin; Hypericum perforatum; St. John's Wort

Indexed keywords

AMITRIPTYLINE; CYTOCHROME P450; D 0496; DYSTO LUX; FLUOXETINE; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; JARSIN 300; LOHYP 57; MAPROTILINE; NEUROTRANSMITTER; PLACEBO; PSYCHOTONIN FORTE; PSYCHOTONIN M; REMOTIV; SERTRALINE; STEI 300; VENLAFAXINE; WS 5572; WS 5573; Z 90017; ZE 117;

CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; HUMAN; HYPERICUM PERFORATUM; META ANALYSIS; NEUROTRANSMITTER UPTAKE; REVIEW; SIDE EFFECT;

DEPRESSIVE DISORDER; DRUG INTERACTIONS; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0036952076     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-002-1300-9     Document Type: Review

References (107)

1. Barbenel DM, Yusufi B, O'Shea D, Bench CJ (2000) Mania in a patient receiving testosterone replacement postorchidectomy taking St. John's wort and sertraline. J Psychopharmacol 14: 84-86
2. Barnes J, Anderson LA, Phillipson JD (2001) St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol 53: 583-600
3. Bergmann R, Nubner J, Demling J (1993) Behandlung leichter bis mittelschwerer Depressionen. Therapiewoche Neurologie/Psychiatrie 7: 235-240
4. Bon S, Hartmann K, Kuhn M (1999) Schweiz Apothekenzeitung 16: 535-536
5. Brenner R, Azbel V, Madhusoodanan S, Pawlowska M (2000) Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clin Ther 22: 411-419
6. Brenner R, Madhusoodanan S, Pawlowska M, Czobor P (2001) St john's wort and major depression. JAMA 286: 43-45
7. Brockmöller J, Reum T, Bauer S, Kerb R, Hübner WH, Roots I (1997) Hypericin and pseudohypericin - pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 30 [Suppl]:94-101
8. Butterweck V, Jürgenliemk G, Nahrstedt A, Winterhoff H (2000) Flavonoids from hypericum perforatum show antidepressant activity in the forced swimming test. Planta Medica 66: 3-6
9. Calapai G, Crupi A, Firenzuoli F, Costantino G, Inferrera G, Campo GM, Caputi AP (1999) Effects of Hypericum perforatum on levels of 5-hydroxytrypta mine, noradrenaline and dopamine in the cortex, diencephalon and brainstem of the rat. J Pharm Pharmacol 51: 723-728
10. Calapai G, Crupi A, Firenzuoli F et al. (2001) Serotonin, norepinephrine and dopamine involvement in the antidepressant action of hypericum perforatum. Pharmacopsychiatry 34: 45-49
11. Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Muller WE (1998) Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci 63: 499-510
12. Chatterjee SS, Noldner M, Koch E, Erdelmeier C (1998) Antidepressant activity of hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry 31 [Suppl]: 7-15
13. Cohen HW, Marantz PR (2001) St John's wort and major depression. JAMA 286: 42-43
14. Connor TJ, Leonard BE (1998) Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci 62: 583-606
15. Cott JM, Rosenthal N, Blumenthal M (2001) St John's wort and major depression. JAMA 286: 42-45
16. Czekalla J, Gastpar M, Hubner WD, Jager D (1997) The effect of hypericum extract on cardiac conduction as seen in the electrocardiogram compared to that of imipramine. Pharmacopsychiatry 30: 86-88
17. Deltito J, Beyer D (1998) The scientific, quasi-scientific and popular literature on the use of St. John's Wort in the treatment of depression. J Affect Disord 51: 345-351
18. Demott K (1998) St. John's wort tied to serotonin syndrome. Clin Psychiatry News 26: 28
19. De Smet PA, Nolen WA (1996) St John's wort as an antidepressant. BMJ 313: 241-242
20. Dunner DL (2001) Acute and maintenance treatment of chronic depression. J Clin Psychiatry 62 [Suppl]: 10-16
21. Ernst E (1995) St. John's wort,an antidepressant? A systematic criteria-based review. Phytomedicine 2: 67-71
22. ESCOP - European Scientific Cooperative on Phytotherapy: Monographs on the medical use of plant drugs - Hyperici herba. Elburg: ESCOP, 1996
23. Faltermaier-Temizel M, Laakmann G, Baghai T, Kuhn K (1997) Predictive factors for therapeutic success in depressive patients. Nervenarzt 68: 62-66
24. Fiebich BL, Hollig A, Lieb K (2001) Inhibition of substance P-induced cytokine synthesis by St. John's wort extracts. Pharmacopsychiatry 34 [Suppl 1]: 26-28
25. Fomous CM, Cardellina JH 2nd (2001) St John's wort and major depression. JAMA 286: 42-45
26. Franklin M, Chi J, McGavin C et al. (1999) Neuroendocrine evidence for dopaminergic actions of hypericum extract (LI 160) in healthy volunteers. Biol Psychiatry 46: 581-584
27. Franklin M, Cowen PJ (2001) Researching the antidepressant actions of Hypericum perforaturn (St. John's wort) in animals and man. Pharmacopsychiatry 34 [Suppl 1]: 29-37
28. Fugh-Berman A (2001) St John's wort and major depression. JAMA 286: 43-45
29. Gaster B, Holroyd J (2000) St John's wort for depression: a systematic review. Arch Intern Med 160: 152-156
30. Gordon JB (1998) SSRIs and St. John's wort: possible toxicity? Am Fam Phys 57: 950
31. Greenberg P, Stiglin L, Finkelstein S, Berndt E (1993)The economic burden of depression in 1990. J Clin Psychiatry 54: 405-418
32. Greeson JM, Sanford B,Monti DA (2001) St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology (Berl) 153: 402-414
33. Grush LR, Nierenberg A, Keefe B, Cohen LS (1998) St John's wort during pregnancy. JAMA 280:1566
34. Hänsgen HD, Vesper J (1996) Antidepressive effectiveness of a highly-dosed hypericum extract. Münch Med Wochenschr 138: 29-33
35. Harrer G, Schmidt U, Kuhn U, Biller A (1999) Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine. Drug Res 49: 289-296
36. Hippius H (1998) St John's Wort (Hypericum perforatum) - herbal antidepressant. Curr Med Res Opin 14: 171-184
37. a. Hypericum Depression Trial Study Group (2002) Effect ov Hypericum perforatum (St. John's Wort) in major depressive disorder: a randomized controlled trial. JAMA 287: 1807-1814
38. Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I (1999) Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum). Clin Pharmacol Ther 66: 338-345
39. Judd L (1995) Mood disorders in the general population represent an important and worldwide public health problem. Int Clin Psychopharmacol 10 [Suppl 4]: 5-10
40. Kalb R, Arnoldt KH, Kleemann A (2000) Langzeitbehandlung mit Johanniskraut-Extrakt LI 160 - Ergebnisse einer offenen multizentrischen Therapiestudie zur Wirksamkeit und Verträglichkeit über 12 Monate bei Patienten mit depressiven Erkrankungen. Allgemeinarzt 6: 428-433
41. Kalb R,Trautmann-Sponsel RD, Kieser M (2001) Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial. Pharmacopsychiatry 34: 96-103
42. Kasper S (2001) Hypericum perforatum - a review of clinical studies. Pharmacopsychiatry 34 [Suppl 1]: 51-55
43. Kientsch U, Burgi S, Ruedeberg C, Probst S, Honegger UE (2001) St. John's wort extract ZE 117 (Hypericum perforatum) inhibits norepinephrine and serotonin uptake into rat brain slices and reduces 3-adrenoceptor numbers on cultured rat brain cells. Pharmacopsychiatry 34 [Suppl 1]: 56-60
44. Kim HL, Streltzer J, Goebert D (1999) St. John's wort for depression: a meta-analysis of well-defined clinical trials. J Nerv Ment Dis 187: 532-538
45. Laakmann G, Schüle C, Baghai T, Kieser M (1998) St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 31 [Suppl]: 54-59
46. Lantz MS, Buchalter E, Giambanco V (1999) St. John's wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatr Neurol 12: 7-10
47. Leber P (1986) The placebo control in clinical trials (a view from the FDA). Psychopharmacol Bull 22: 30-32
48. Lenoir S, Degenring FH, Saller R (1999) A double-blind randomised trait to investigate three different concentrations of a standardised fresh plant extract obtained from the shoot tips of hypericum perforatum L. Phytomedicine 6: 141-146
49. Leonard BE (1995) Mechanism of action of antidepressants. CNS Drugs 4 [Suppl 1]: 1-12
50. Linde K, Ramirez G, Mulrow D, Pauls A, Weidenhammer W, Melchart D (1996) St. John's wort for depression - an overview and meta-analysis of randomized clinical trials. BMJ 313: 253-258
51. Maisenbacher P, Kovar PA (1992) Adhyperforin - a homologue of hyperforin from Hypericum perforatum. Planta Med 58: 291-293
52. Markowitz JS, DeVane CL, Boulton DW, Carson SW, Nahas Z, Risch SC (2000) Effect of St. John's wort (Hypericum perforatum) on cytochrom P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 66: 133-139
53. Maurer A, Johne A, Bauer S (1999) Interaction of St. John's wort extract with phenprocoumon. Eur J Clin Pharmacol 55: A22
54. Miller JL (2000) Interaction between indinavir and St. John's wort reported. Am J Health Syst Pharm 57: 625-626
55. Moses EL, Mallinger AG (2000) St. John's wort: three cases of possible mania induction. J Clin Psychopharmacol 20: 115-117
56. Mowbray RM (1972) The Hamilton Rating Scale for depression: a factor analysis. Psychol Med 2: 272-280
57. Müldner H, Zöller M (1984) Antidepressive Wirkung eines auf dem Wirkstoffkomplex Hypericin standardisierten Hypericum-Extraktes. Arzneimittelforschung 34: 918-920
58. Müller MJ, Szegedi A, Wetzel H, Benkert O (2000) Moderate and severe depression. Gradations for Montgomery-Asberg Depression Rating Scale. J Affect Disord 60: 137-140
59. Müller WE, Rolli M, Schäfer C, Hafner U (1997) Effects of hypericum extract (LI 160) in biochemical models of antidepressant acitivity. Pharmacopsychiatry 30 [Suppl 2]: 102-107
60. Müller WE, Singer A, Wonnemann M, Hafner U, Rolli M, Schäfer C (1998) Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 31 [Suppl 1]: 16-21
61. Muruganandam AV, Ghosal S, Bhattacharya SK (2000) The role of xanthones activity of Hypericum perforatum involving dopaminergic and serotonergic systems. Biogenic Amines 15: 553-557
62. Nathan PJ (2001) Hypericum perforatum (St John's Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology. J Psychopharmacol 15: 47-54
63. Neary JT, Bu Y (1999) Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes. Brain Res 816: 358-363
64. Nebel A, Schneider BJ, Baker RK, Kroll DJ (1999) Potential metabolic interaction between St. John's wort and theophylline. Ann Pharmacother 33: 502
65. Nierenberg AA, Burt T, Matthews J, Wess AP (1999) Mania associated with St. John's wort. Biol Psychiatry 46: 1707-1708
66. Philipp M, Kohnen R, Hiller KO (1999) Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. BMJ 319: 1534-1538
67. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J (2000) Indinavir concentrations and St. John's wort. Lancet 355(9203): 547-548
68. Rabkin JG, Klein DF (1987) The clinical measurement of depressive disorders. In: Marsella AJ, Hirschfeld RMA, Katz M (eds) The Measurement of Depression. Chichester, Wiley UK, pp 30-83
69. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH (2000) St. John's wort: effect on CYP3A4 acitivity. Clin Pharmacol Ther 67: 451-457
70. Rolli M, Schäfer C, Müller WE (1995) Effect of hypericum extract (LI 160) on neurotransmitter binding and synaptosomal uptake systems. Pharmacopsychiatry 28: 207
71. Sackheim HA, Devanand DP, Nobler MS (1995) Electroconvulsive therapy. In: Psychopharmacology: The Forth Generation of Progress. Edited by Bloom FE, Kupfer DJ. Raven Press, New York, pp 1123-1141
72. Schrader E, Meier B, Brattström A (1998) Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicentre study. Hum Psychopharmacol 13: 163-169
73. Schrader E (2000) Equivalence of St. John's wort extract (ZE 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 15: 61-68
74. Schüle C, Baghai T, Ferrera A, Laakmann G (2001) Neuroendocrine effects of Hypericum extract WS 5570 in 12 healthy male volunteers. Pharmacopsychiatry 34 [Suppl 1]: 127-133
75. Shelton RC, Keller MB, Gelenberg A et al. (2001) Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA 285:1978-1986
76. +. J Pharmacol Exp Ther 290: 1363-1368
77. Anonym (1997) St. John's wort. Med Lett Drugs Ther 39: 107-108
78. Suzuki O, Katsumata Y, Oya M, Bladt S, Wagner H (1984) Inhibition of monoamine oxidase by hypericin. Planta Med 50: 272-274
79. Terluin B, van Hout H (2000) Treatment of mild depression in elderly patients. JAMA 284: 2993-2994
80. Teufel-Mayer R,Gleitz J (1997) Effects of long-term administration of hypericum extracts on the affinity and density of the central serotonergic 5-HT1 A and 5-HT2 A receptors. Pharmacopsychiatry 30 [Suppl 2]: 113-116
81. Thiele B, Brink I, Ploch M (1994) Modulation of cytokine expression by hypericum extract. J Geriatr Psychiatry Neurol 7 [Suppl 1]: 60-62
82. Volz HP (1997) Controlled clinical trials of hypericum extracts in depressed patientsan overview. Pharmacopsychiatry 30 [Suppl 2]: 72-76
83. Volz HP, Eberhard R, Grill G (2000) Efficacy and tolerance of the St. John's wort extract D-0496 in mild to moderate depression - a placebo-controlled, double-blind, 8-week trial. Nervenheilkunde 19: 401-405
84. Volz HP, Laux P (2000) Potential treatment for subthreshold and mild depression: a comparison of St. John's wort extracts and fluoxetine. Compr Psychiatry 41 [Suppl 1]: 133-137
85. Volz HP, Murck H, Möller HJ (2001) St. John's wort extract (LI 160) in somatoform disorders. Results of a placebo-controlled trial (submitted)
86. Vorbach EU, Arnold KH, Hübner WD (1997) Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry 30 [Suppl]: 81-85
87. Wagner H, Bladt S (1994) Pharmaceutical quality of hypericum extracts. J Geriatr Psychiatry Neurol 7 [Suppl 1]: 65-68
88. Wheatley D (1997) LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients - a controlled 6-week trial. Pharmacopsychiatry 30 [Suppl 2]: 77-80
89. Williams JW Jr, Barrett J, Oxman T et al. (2000) Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults. JAMA 284: 1519-1526
90. Witte B, Harrer G, Kaptan T, Podzuweit H, Schmidt U (1995) [Treatment of depressive symptoms with a high concentration hypericum preparation. A multicenter placebo-controlled double-blind study]. Fortschr Med 113: 404-408
91. Woelk H (2000) Comparison of St. John's wort and imipramine for treating depression: randomised controlled trial. BMJ 321: 536-539
92. Wonnemann M, Singer A, Muller WE (2000) Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St. John's Wort: the role of amiloride sensitive sodium conductive pathways. Neuropsychopharmacology 23: 188-197
93. Hoffmann J, Kühl ED (1979) Therapie von depressiven Zuständen mit Hypericin. Z Allgemeinmed 55: 776-782
94. Schlich D, Braukmann F, Schenk N (1987) Behandlung depressiver Zustände mit Hyopericin. Psycho 13: 440-447
95. Schmidt U, Schenk N, Schwarz I, Vorberg G (1989) Zur therapie depressiver Verstimmungen. Psycho 15: 665-671
96. Halama P (1991) Wirksamkeit des Johanniskrautes LI160 bei depressiven Verstimmungen. Nervenheilkunde 10: 250-253
97. Osterheide M, Schmidtke A, Beckmann H (1992) Behandlung depressiver Symptome mit Hypericin (Johanniskraut): eine placebokontrollierte Doppelblindstudie. Fortschr Neurol Psychatr 60 [Suppl 2]: 210-211
98. Reh C, Laux P, Schenk N (1992) HypericumExtrakt bei Depressionen - eine wirksame Alternative. Therapiewoche 42: 1576-1781
99. König CD (1993) Hypericum perforatum L (gemeines Johannskraut) als Therapeutikum bei depressiven Verstimmungen - eine Alternative zu synthetischen Arzneimitteln. Thesis, Univ Basel
100. Lehrl S, Woelk H (1993) Ergebnisse von Messungen der kognitiven Leistungsfähigkeit bei Patienten unter der Therapie mit Johanniskraut. Nervenheilkunde 12: 281-284
101. Quandt J, Schmidt U, Schenk N (1993) Ambulante Behandlung leichter und mittelschwerer depressiver Verstimmungen. Allgemeinarzt 2: 97-102
102. Schmidt U, Sommer N (1993) Johanniskraut-Extrakt zur ambulanten Therapie der Depression. Fortschr Med 111: 339-342
103. Hänsgen KD, Vesper J, Ploch M (1994) Multi-center double-blind study examining the antidepressant effectiveness of the Hypericum extrakt LI160. J Geriatr Psychiatry Neurol 7 [Suppl 1]: 15-18
104. Hübner WD, Lande S, Podzuweit H (1994) Hypericum treatment of mild depression with somatic symptoms. J Geriatr Psychiatry Neurol 7 [Suppl 1]: 12-15
105. Sommer H, Harrer G (1994) Placebo-controlled double-blind study examining the effectiveness of a Hypericum preparation in 105 mildly depressed patients. J Geriatr Psychiatry Neurol 7 [Suppl 1]: 9-11
106. Harrer G, Hübner WD, Podzuweit H (1994) Effectiveness and tolerance of the Hypericum extract LI160 compared to maprotiline: a multi-center double-blind study. J Geriatr Psychiatry Neurol 7 [Suppl 1]: 24-28
107. Vorbach EU, Hübner WD, Arnoldt KH (1994) Effectiveness and tolerance of the doubleblind study in 135 outpatients. J Geriatr Psychiatry Neurol 7 [Suppl 1]: 19-25